- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Rx Dilemma
How much is too much to pay for a new dermatological drug? Your answer likely will depend on whether you're a developer or doctor, a patient or a third-party payer. Regardless of one's perspective, it doesn't take a medical degree to recognize the fact that prescription prices have risen precipitously in recent years, a trend which continued in 2002 and is expected to persist well beyond this year.
Related Videos
Melinda Gooderham, MD, MSc, FRCPC: Minimal Systemic Exposure of Delgocitinib Cream in Chronic Hand Eczema
Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies
Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children
Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists
Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability
Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis
Utilizing Gene Expression Profiling to Avoid Unnecessary Interventions in a 72-Year-Old Woman With Melanoma
Differentiating Between JAK Inhibitors in Clinical Practice
IL-17 Inhibitor Treatment Impact on Quality of Life in Psoriasis and Psoriatic Arthritis
Clinical Attributes of IL-17 Inhibitors in Psoriasis
Related Content
